RARE Ultragenyx Pharmaceutical Inc

$RARE patience its going to go higher $PDSB patience its going to go higher Theyneverlisten patience we will print more

$RARE $RARE now combines 6 approved therapies, 2026 revenue guidance of $730–760M that excludes the new launches, two newly commercialized gene therapies, and a major cost reduction plan targeting profitability in 2027 — meaning revenue growth and margin expansion could happen at the same time, a rare combination for a company of this size.

$RARE 6 approved drugs, 2026 revenue guidance of $730–760M that excludes the new launches, two newly commercialized gene therapies, and a major cost reduction plan targeting profitability in 2027 , meaning revenue growth and margin expansion could happen at the same time, a rare combination for a company of this size.

$RARE It has bottomed at 14 and is posed for recovery - multi-drug companies with portfolio of FDA-approved drugs and extensive pipeline like the one RARE has - they always move on even after setbacks like the one with Angelman. September is always the weakest month for stocks, and also add the geopolitical and macro noise from oil prices and bond yields soaring.

$RARE RARE could easily gap toward $18–$20, depending on what the two PRVs ultimately sell for. But if there’s still NO PRV sale announcement soon, that gets even more interesting. My theory is that a Big Pharma could be negotiating to acquire the entire company and take both valuable PRVs as part of the package. With RARE’s approved products, pipeline, and two PRVs, I believe a $30–$35 buyout is very possible. Something may be happening behind the scenes.

When $RARE takes off I think I’m going to buy a 1969 Trans Am & start doing cocaine again.

$RARE Ultragenyx, a rare-disease drugmaker, will keep about $168M, not $210M, from selling its FDA priority review voucher: its 8-K says 20% of the gross goes to the NIH under a 2018 license. That is non-dilutive cash worth about 1.7 quarters of operating burn ($97M in Q2), on top of $436M held at June 30. The company says it supports its path to profitability in 2027. Against that: it is a one-time sale, not recurring revenue. Closing waits on an antitrust review.

$RARE $SMMT Quiet ones that would not surprise me get taken out. Theyneverlisten I give you these when nobody is watching

$RARE Is it possible that RARE share price closes green today? I've seen it happen many times. The chart does not lie we're moving up!

$RARE - At around $15, RARE offers an attractive long-term risk/reward because the market has already heavily discounted the GTX-102 setback, while the company still has a growing commercial business led by Crysvita. The recent approvals of FAYUVI and GENGLYCOS, combined with a pipeline including DTX301 and UX701, provide multiple potential growth drivers over the next several years. If Ultragenyx executes well and reaches profitability as planned, the current valuation could prove significantly undervalued. Disclouse - I am an longterm Investor with 10K share with an average price of $20.56

$RARE this isnt real. No one is selling shares for $14.35. We simply are witnessing short sellers who are stuck and dont want to cover yet.

$RARE - No major events expected in the next 12 months? Are you serious! Goal: Targeting corporate profitability by 2027 while supporting 5 approved products. Ultragenyx announced two major gene therapy FDA approvals within a month.

$RARE $RARE looks dramatically mispriced. Six FDA-approved therapies, $214M in Q2 revenue, two new high-margin gene therapy launches, and a clear path to profitability in 2027 — yet the market cap is only ~$1.4B. Compare that with mature rare-disease peers valued at many billions. Six approved therapies. Growing revenue. New launches. Profitability ahead. At this valuation, the disconnect is hard to ignore. $45 may be much closer than the market thinks.

$RARE 👈ridiculously low price…. Loading here again. Chart. Massive pipeline. Way undervalued. They will find it.

$RARE Today's - Resolved patent litigation with Navinta, permitting a non-exclusive, royalty-free generic DOJOLVI entry on January 1, 2033.

$RARE This. At Ultragenyx, we have developed one of the largest advanced clinical gene therapy portfolios in the industry.

$RARE I’ve been trading before many of you were in diapers , when I see this high institutional ownership , 20% short float and positive news I go BIG long. GLTA!

$RARE That reverse H&S will break the neckline at $16.15 then surge to $20 near term. Setting up for the PRV sale news. Tomorrow possibly.

$RARE Wanted to re-add this below $13, which seems very tough considering the 30-year yield is at its highest level since 2002. Eventually, that should cool off, and this is sitting right here. Re-added already! GL everyone. This seems like the bottom for the next run.

$RARE - This is a multi bagger. Once stock prices starts moving, these so called analysts will start increasing the Target price. In few years this stock will be back to $60+ once we have better visibiliity around the last two approval adoption.